Mayo Clinic Arizona is pioneering the future of cardiovascular care through transformational research in cardiac regeneration and translational cardiovascular science. Our Department of Cardiovascular Medicine seeks an exceptional research scientist to establish a cutting-edge program addressing fundamental challenges in cardiovascular disease through innovative approaches in regenerative medicine, cardio-oncology, or related translational research areas.
This position directly supports Mayo Clinic's transformational vision to shift healthcare from reactive treatment to predictive prevention, aligning with:
Genesis Initiative: Revolutionizing transplant discovery and developing alternatives to cadaveric transplant through pioneering science in cellular engineering, advanced cell therapy products, and bioartificial organ systems.
Precure Initiative: Developing platform products that enable prediction and prevention of diseases through biological signatures, real-time sensing technologies, and algorithmic approaches.
Bold. Forward. Transformation: Accelerating the path from discovery to clinical treatment, leveraging AI and data intelligence to reimagine clinical trials and therapeutic development.
Our department has established significant research infrastructure in cardiac regeneration, with active programs focusing on cell-based therapy for ischemic heart disease, enhancement of hiPSC-derived cardiomyocyte regenerative potency, neonatal heart regeneration and molecular pathways regulating cardiomyocyte proliferation, and nanoparticle-based, cell-type specific drug delivery systems. Our diverse extramural and intramural funding portfolio, inclusive of four active NIH R01 grants totaling over $8 million, demonstrates significant investigator excellence and national competitiveness.
We seek an innovative investigator who will establish a complementary and symbiotic research program in cardiac regeneration, cardio-oncology, or related translational cardiovascular science areas that align with our department's strategic vision and existing research infrastructure.
Preferred Expertise
Candidates should demonstrate technical excellence and a proven track record in cardiovascular research. We welcome applications from investigators in diverse but complementary research areas including:
Essential Qualifications:
Areas of Particular Interest:
Additional Preferred Qualifications:
Ideal Candidate Profile
The successful candidate will join the Department of Cardiovascular Medicine and contribute to enterprise-wide research and translational activities. Mayo Clinic Arizona is part of a three-site integrated academic medical center with expectations to integrate locally and collaborate broadly across the enterprise. The research program will be based at Mayo Clinic Arizona (Scottsdale or Phoenix campus).
Department of Cardiovascular Medicine at Mayo Clinic Arizona
The Department of Cardiovascular Medicine at Mayo Clinic Arizona is one of the most dynamic and rapidly growing cardiovascular programs in the United States, encompassing six specialized divisions (Cardiac Electrophysiology, Interventional and Structural Heart, Cardiovascular Imaging, Advanced Heart Failure and Transplant, Cardiac Subspecialties, and Comprehensive and Preventive Cardiology), with over 80 providers serving more than 40,000 patient visits annually. Our heart transplant program ranks among the best in the nation, with the shortest median wait time to transplant in Arizona and a 3-year patient survival rate of 92.2%, 9th highest in the U.S. We perform the full spectrum of advanced cardiovascular procedures, from pulsed field ablation and complex coronary interventions to TAVR, transcatheter valve repair, and ventricular assist device implantation, supported by a state-of-the-art Cardiovascular Artificial Intelligence Core Team that is redefining early detection and personalized treatment.
Research is a cornerstone of our departmental identity. In 2025, our faculty produced 184 peer-reviewed publications, with 79% of staff authoring at least one article, and supported 39 active grants and 73 research professionals. Our cardiac regeneration program alone holds four active NIH R01 grants totaling over $8 million, and new research scientist hires will benefit from a rich collaborative infrastructure that includes shared core facilities, an integrated electronic health record, and direct access to Mayo Clinic’s enterprise-wide biorepositories and translational science platforms. The successful candidate will join a department that couples world-class clinical volume with a deeply committed research culture, creating an unparalleled environment to develop and sustain an independent, nationally competitive research program.
Highlights of Mayo Clinic Research Enterprise
About Mayo Clinic
Mayo Clinic is top ranked in more specialties than any other care provider according to U.S. News & World Report. With a 73,000-person workforce, Mayo Clinic cares for more than 1.3 million people each year with serious or complex illnesses from all 50 U.S. states and 130 countries. Mayo Clinic is the largest not-for-profit, multidisciplinary academic medical center in the world with over 4,000 physicians and scientists in an integrated multi-campus system spanning the globe.
The unified mission at Mayo Clinic is to provide the best patient care, backed by our expertise and supported by innovation in education, research and practice, to bring hope and healing in times of need. We embrace collegial relationships among campuses (Arizona, Florida and Minnesota) allowing for best practices and innovation to help solve the most serious complex medical challenges, one patient at a time.
Mayo Clinic Arizona is making significant investments in both the physical and technological future of health care, through doubling the size of the Mayo Clinic campus in Phoenix, inclusive of practice, education, and research activities. Mayo Clinic's campuses in Arizona are in Phoenix and Scottsdale, in the beautiful Sonoran Desert. The region is known as the Valley of the Sun, a metropolitan area with more than 4 million residents in 25 cities and towns.
As we work together to put the needs of the patient first, we are also dedicated to our employees, investing in a highly competitive compensation package with substantial long-term institutional and departmental support for salary, personnel, equipment, and travel as well as a competitive startup package all designed to ensure immediate and continued success. Additional benefits for faculty at Mayo Clinic include intramural funding opportunities for research and innovation. We provide an outstanding, comprehensive benefits package that includes plenty of options for medical, dental and vision care; flexible spending accounts; life insurance; short- and long-term disability coverage; travel allowance; generous time away; and more! We are proud to be among the few U.S. companies to provide a pension benefit at no cost to employees plus you can add the Mayo 403(b) plan which features an employer match.
Mayo Clinic is a nonprofit medical organization that provides high-quality health care by combining clinical practice, education, and research. It treats patients with serious and complex illnesses through multidisciplinary teams across a network in the United States and internationally. It funds and conducts patient care, research, and education, and participates in Medicare programs and health-system initiatives. Its goal is to improve patient outcomes and advance medical knowledge while expanding access to personalized care.
Company Size
10,001+
Company Stage
Grant
Total Funding
$360.1M
Headquarters
Rochester, Minnesota
Founded
1978
See people who can refer or advise you
Goodfire's EVEE reclassifies a hearing-loss variant scoring 4.2M entries. Goodfire's EVEE system scored every ClinVar variant with an interpretable probe on Evo 2 embeddings, triggering a real reclassification of a hearing loss mutation. · 4 hrs ago Read 6 min * Goodfire and Mayo Clinic's EVEE scored all 4.2M ClinVar variants with interpretable predictions. * MEPE c.209_212del was reclassified as likely pathogenic, linked to hearing loss. * Pathogenicity probe hits 0.997 AUROC on 839k SNVs, 0.991 on indels zero-shot. * Built on frozen Evo 2 embeddings with covariance-based sequence pooling, not end-to-end fine-tuning. * Annotation probes plus Claude Sonnet 4.6 generate readable disruption hypotheses per variant. * Roughly 2M variants of uncertain significance now have structured mechanistic hypotheses attached. How EVEE helped reclassify a hearing-loss variant. Goodfire's machine-learning system helped move a MEPE variant associated with hearing loss from "uncertain significance" to "likely pathogenic" in ClinVar, the public archive maintained by the National Center for Biotechnology Information. After scoring 4.2 million ClinVar entries, the system highlighted MEPE c.209_212del as a candidate for clinical review. The system, called EVEE, or Evo Variant Effect Explorer, combines a genomic foundation model, small supervised classifiers called probes, and a reasoning large language model. Goodfire developed it with Mayo Clinic to rank variants, predict disrupted biological features, and generate testable explanations of how a mutation might cause disease. Goodfire describes the methods in its research report. Two million unresolved variants. ClinVar aggregates variant classifications from clinical laboratories, researchers, expert panels, and professional organizations. When sequencing identifies a potentially relevant mutation, clinicians consult these assertions alongside a patient's symptoms, family history, inheritance pattern, and other evidence. A variant of uncertain significance, commonly shortened to VUS, lacks enough evidence for a confident classification. A VUS generally cannot guide diagnosis or medical management. In the ClinVar snapshot analyzed by Goodfire, roughly 2 million of 4.2 million entries carried that label. Current predictors cover different parts of the problem. Protein-focused systems such as AlphaMissense primarily evaluate missense variants, which change one amino acid. They can miss mutations that alter RNA splicing, gene regulation, or other non-protein mechanisms. Genome-wide tools such as CADD combine more than 100 annotations, but their transformed and interacting features can make an individual prediction difficult to explain. Freeze the model, train the probes. EVEE builds on Evo 2, a neural network trained on billions of DNA bases from organisms across the tree of life. The authors report that Evo 2 was not trained on human genetic-variation records, allowing them to test whether its learned representation of genomic structure transfers to clinical variants. Goodfire freezes Evo 2's parameters and trains lightweight probes on its internal representations, or embeddings. Freezing reduces training cost and preserves the base model, while each probe learns a focused task from labeled examples. * EVEE encodes the reference DNA sequence and the mutated sequence with Evo 2. * Covariance-based pooling summarizes relationships among sequence features. * A pathogenicity probe compares the two representations and assigns a score. * Annotation probes estimate changes to splice sites, regulatory elements, structural domains, and other known features. * A reasoning model combines those signals with gene context to draft a mechanistic hypothesis. Covariance pooling preserves feature co-occurrence across a sequence, such as a motif appearing within a particular structural context. Mean pooling averages positions together and can erase those relationships. The pathogenicity probe operates on the difference between the pooled reference and mutant embeddings. What 0.997 AUROC captures. Goodfire reports strong ranking performance across single-nucleotide variants and short insertions or deletions. AUROC measures how reliably a model ranks pathogenic variants above benign ones across many classification thresholds, with 1.0 representing perfect ranking and 0.5 representing chance. | Evaluation | Scope | AUROC | Training status | | ClinVar single-nucleotide variants | 839,000 variants | 0.997 | Primary variant class | | Short insertions and deletions | Variant count not specified | 0.991 | Zero-shot transfer | The authors also report better performance than classical meta-predictors, protein-specific systems, and other foundation-model approaches across consequence types and conservation levels. EVEE transferred to deep mutational-scanning datasets for BRCA1, BRCA2, TP53, and LDLR, which experimentally measure the effects of many mutations in parallel. AUROC leaves several deployment questions open, including probability calibration, performance within specific patient populations, and the positive predictive value for rare variant classes. Clinical use also requires prospective validation beyond retrospective benchmark labels. Mechanisms in plain language. Annotation probes estimate how a mutation changes recognizable biological features. For each variant, EVEE compares the probe outputs for the reference and mutant sequences, producing a "disruption profile" that identifies the largest predicted changes. Goodfire says the public application uses Claude Sonnet 4.6 to combine the disruption profile, pathogenicity score, and gene context into a natural-language hypothesis. The resulting explanation can suggest mechanisms for expert review, such as altered splicing or disruption of a functional domain. Goodfire evaluated the explanations against 154 ClinVar variants carrying at least three review stars, a level associated with expert-panel or practice-guideline review. An LLM judge scored mechanism coverage, biological accuracy, and specificity. EVEE received a composite score of 3.8 out of 5, compared with 2.8 for explanations generated from variant metadata alone. The MEPE assertion changes. The MEPE variant c.209_212del deletes four bases from the coding sequence, which is expected to shift the gene's reading frame. Goodfire reports that EVEE ranked it highly enough to prompt a focused evidence review and contributed to its classification moving from VUS to likely pathogenic. That category can support a diagnosis when the molecular evidence aligns with phenotype, inheritance, and other clinical findings. ClinVar stores assertions from submitters and can display conflicting classifications for the same variant. A reclassification therefore reflects a changed or added submission, including its evidence and review status. NCBI does not independently adjudicate every assertion deposited in the archive. The MEPE case documents a practical workflow: score millions of records, prioritize a manageable set, generate mechanistic leads, and assemble evidence for expert review. A single successful reclassification does not measure the system's prospective clinical accuracy, but it shows how computational prioritization can enter an established variant-curation process. How to test EVEE. * The free EVEE web app provides precomputed scores and disruption profiles for 4.2 million ClinVar variants. * Users can request natural-language explanations for individual variants, including VUS entries. * Researchers can inspect EVEE's predictions as candidate mechanisms for laboratory testing or manual curation. * The covariance-pooling and probe-based design can be adapted to other genomic prediction tasks built on frozen sequence models. Research guardrails. * Predictions require validation. Pathogenicity scores and generated explanations remain research hypotheses until supported by clinical, functional, or segregation evidence. * Probes reflect their labels. Annotation probes can identify biological concepts represented in their training data. Uncharacterized mechanisms may remain hidden. * Generated prose can fail. The language model may omit relevant evidence, overstate a mechanism, or introduce an unsupported claim. Experts should inspect the underlying scores and sources. * Aggregate metrics have limits. High AUROC does not provide a calibrated patient-level probability or guarantee performance for every gene, ancestry, or variant class. * The explanation evaluation is indirect. An LLM judge offers a scalable comparison, while experimental evidence and specialist review provide stronger validation. * The work remains preliminary. The research is available as a bioRxiv preprint and is undergoing peer review. A pattern beyond genomics. EVEE's architecture turns a foundation model's internal representations into named biological concepts. The frozen model supplies broad sequence features, supervised probes map those features to known annotations, and the language model assembles the results into readable hypotheses. For teams building variant-effect predictors or interpretability systems for scientific models, EVEE offers a concrete reference design. Its broader value will depend on prospective validation, transparent evaluation, and evidence that the generated mechanisms help researchers choose better experiments and clinicians curate variants more efficiently.
5 things to catch. What's happening this week? Today at 5:00 AM News Reporting 1. More medical research Using data from almost 40,000 patients' health records, a team of Mayo Clinic researchers are testing an AI tool to predict one's pancreatic cancer risk. Read all about the research in the Tuesday edition of the Post Bulletin. Zumbrota-Mazeppa knocks off Winona Cotter, relishing new era of Z-M football 2. Century grad a smash hit at UMD Century graduate Paige Decker, now a college senior, has helped guide the University of Minnesota Duluth volleyball team to a 16-1 record this season. She is one of three southeastern Minnesotans on the team, and is one of UMD's best players. PB sports reporter has her story in Tuesday's Sports. 3. Election coverage continues As we get closer to the November election, we'll have more stories in our paper this week. Look out for stories on the auditor's race and the Rochester mayor's race. 4. Making a splash Elise Weingarten has had some outstanding role models to learn from during her time in competitive swimming. Now it's her turn to be a leader on the Mayo High swimming and diving team, while going through the college recruiting process. PB sports reporter Madeline Warren has Weingarten's story on Tuesday. 5. Lack of officials? In the Saturday edition of the Post Bulletin, we'll have a look at how those who are officiating local high school games has changed over time. Look for that story later this week. News Reporting Our newsroom occasionally reports stories under a byline of "staff." Often, the "staff" byline is used when rewriting basic news briefs that originate from official sources, such as a city press release about a road closure, and which require little or no reporting. At times, this byline is used when a news story includes numerous authors or when the story is formed by aggregating previously reported news from various sources. If outside sources are used, it is noted within the story. More stories for you. Get daily personally-crafted news reviews from Editor Jeff Pieters in your inbox. Conversation
Can you live longer for $5,500? Longevity clinics are the buzzy new trend at nonprofit hospitals. Northwestern Medicine, Weill Cornell, and Mayo Clinic have all launched cash-pay longevity clinics. Oct. 6, 2026 Todd underwent longevity assessments at hospital clinics in two states for this story, measuring the health trajectories of her heart, brain, lungs, eyes, ears, and more, as well as her strength and fitness. This is Part 1 of Selling Longevity, which examines the science of longevity and the risk of jumping ahead of research in search of profits. CCHICAGO - I was walking briskly on a steep treadmill, wearing a mask that evoked the villain Bane from "Batman." Prince crooned back-handed compliments over an iPad speaker to keep my energy up, promising I had to be neither rich nor cool to be his girl. Every so often, the woman standing next to me asked me to point at the color-coded sheet ranking my state of exertion from 1 (roughly, "I could do this all day") to 10 ("I not only hate this but am about to keel over if you don't slow this thing down"). The goal was to get to 10. Pushing myself to achieve difficult physical goals does not come naturally. I can't go on, I thought. I went on. This was the VO2 Max test, which shows how efficiently the body uses oxygen ("V" stands for volume, "O2" for oxygen) and is considered medicine's most accurate measure of cardiorespiratory fitness. It was the last in a barrage of assessments I'd undertaken at a shiny longevity clinic affiliated with Northwestern University - part of a $5,500 annual package. The quest to defeat the indignities of aging has long provoked costly and questionable practices, from the 1920s doctors who believed in the rejuvenating power of grafted monkey testicles to Bryan Johnson's since-abandoned blood transfusions from his teenage son. Now some of the nation's most prestigious health systems are jumping into the growing business of longevity. They promise a rigorous scientific approach to helping people preserve their youthful vigor for as long as they can, with assessments that give patients more detailed pictures of their current physical conditions and aging trajectories than they'd get at a typical doctor's visit. Some critics, however, question how to reconcile the clinics' high out-of-pocket costs with hospitals' nonprofit status and charitable missions, and warn that in their zeal to attract paying customers, they're offering tests that lack sufficient evidence showing they actually improve people's health. * Sarah Todd Reporter, Commercial Determinants of Health Sarah covers how industries like food and tobacco affect Americans' bodies and minds. Her interests include ultra-processed foods; smoke-free tobacco; and wellness trends like perimenopause products and peptides. Confidential tips can be sent on Signal at sarahlizchar.47.
Chuck Schumer slams Hyde Amendment on 50th anniversary, says abortion restrictions force Americans to choose between care, rent, food: 'health care must not be a privilege' Snigdha Gairola Sat, October 3, 2026 at 1:30 PM PDT Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Senate Minority Leader Chuck Schumer (D-N.Y.) marked the 50th anniversary of the Hyde Amendment by arguing that its restrictions on federal abortion funding have created financial barriers for low-income Americans seeking abortion care. Schumer criticizes Hyde Amendment. On Wednesday, Schumer said on X that the Hyde Amendment had spent five decades limiting access to abortion care for people who could not afford to pay out of pocket. "Today the Hyde Amendment turns 50 years old," he wrote. He described it as "50 years of denying critical abortion care to people who can't afford it." Don't Miss: Schumer said the policy had forced people to choose between health care and essential expenses, including "rent, food, child care, or other necessities." He also argued that the amendment had made access to health care dependent on a person's financial circumstances. "Health care must not be a privilege for people who can afford it," Schumer said. Today the Hyde Amendment turns 50 years old. 50 years of denying critical abortion care to people who can't afford it. 50 years of forcing people to choose between paying for health care and paying for rent, food, child care, or other necessities. 50 years of making access to... - Chuck Schumer (@SenSchumer) September 30, 2026 Schumer criticized VA abortion policy. Last year, Schumer criticized the Trump administration's policy restricting abortion access for veterans, calling it a "betrayal." He said the policy barred veterans from obtaining abortion care even in cases of rape, incest and life-threatening complications, describing it as a "war against access to safe abortion." Health care access and AI. On Monday, Eli Lilly and Company launched the Lilly Change the Course Commitment to expand access to diabetes and obesity treatments in low- and middle-income countries by 2040, focusing on clinical development, medicine registrations and local health systems. In July, former Transportation Secretary Pete Buttigieg said broad support existed for affordable health care, stronger public schools and infrastructure investment, including in politically competitive and Republican-leaning areas. Previously, Microsoft Corp. AI CEO Mustafa Suleyman said health care could be AI's most important application as Microsoft and Mayo Clinic partnered to develop a health care-focused AI model aimed at improving diagnoses, treatment decisions and patient outcomes. Building wealth across more than just the market. Building a resilient portfolio means thinking beyond a single asset or market trend. Economic cycles shift, sectors rise and fall, and no one investment performs well in every environment. That's why many investors look to diversify with platforms that provide access to real estate, fixed-income opportunities, precious metals, and even self-directed retirement accounts. By spreading exposure across multiple asset classes, it becomes easier to manage risk, capture steady returns, and create long-term wealth that isn't tied to the fortunes of just one company or industry. Arrived. Backed by Jeff Bezos, Arrived Homes makes real estate investing accessible with a low barrier to entry. Investors can buy fractional shares of single-family rentals and vacation homes starting with as little as $100. This allows everyday investors to diversify into real estate, collect rental income, and build long-term wealth without needing to manage properties directly. Realberry. For accredited investors looking beyond traditional stocks and bonds, Realberry provides access to institutional-quality real estate investments, including a preferred equity opportunity in the 297-room Hyatt Place Boston Seaport. The firm has invested across multiple property types and markets, with 13 million square feet of real estate across seven U.S. states and $481 million in cumulative distributions paid to investors as of Q4 2025. Skybound Entertainment. Entertainment franchises can become valuable long-term assets when they successfully expand across multiple platforms. Skybound Entertainment, the company behind The Walking Dead and Invincible, develops original intellectual property that spans comics, television, film, video games, merchandise, and licensing. With more than 250 IPs in its portfolio and a strategy focused on retaining franchise rights while scaling successful stories across media, Skybound offers investors exposure to the growing entertainment and creator economy through a private company rather than traditional public market investments. American PowerGen. As artificial intelligence drives a surge in electricity demand, reliable power generation is becoming a critical part of the technology ecosystem. American PowerGen is developing natural gas-fired power plants in Texas, a fast-growing market fueled by AI data centers, manufacturing expansion, and population growth. By advancing projects through permitting, fuel supply, and grid interconnection, the company is positioning itself to help meet rising energy needs while offering investors exposure to the infrastructure supporting the next wave of AI and industrial growth. EquityMultiple. For accredited investors looking beyond stocks and bonds, EquityMultiple provides access to vetted commercial real estate deals starting at $5,000, with only ~5% of opportunities passing their due diligence process. FarmTogether. Farmland has historically held its value through market volatility and delivered returns uncorrelated to stocks and bonds. For accredited investors, FarmTogether offers direct access to high-quality U.S. farmland starting at $15,000 - fully managed, with no landlord headaches. Fundrise. Private real estate and private credit can add income and stability to a stock-heavy portfolio. Fundrise offers access to diversified private real estate and credit strategies through an easy-to-use platform, with professionally managed portfolios designed to generate passive income and long-term growth.
Elmo helps children discover the importance of a good night's sleep in new picture book. Time to Read: 1 min - 281 words Sesame Street favourite joins forces with Mayo Clinic Press Kids for a new book offering practical tips to help children settle at bedtime Elmo is back with a new adventure designed to help young children understand the importance of sleep - and discover that winding down at bedtime can be easier than they think. Elmo Isn't Sleepy!, a new picture book from Sesame Street and Mayo Clinic Press Kids, will be released on 13 October. The story follows the much-loved red character as he skips his nap, gets too excited to fall asleep and learns how rest helps him feel his best. Created to support families navigating the challenges of bedtime and naptime, the book combines a playful story with practical advice to help children manage their feelings and develop healthier sleep habits. With guidance from Mayo Clinic paediatric psychologist Dr Emily McTate and the Sesame Street characters, young readers are encouraged to recognise that all feelings are safe to experience, while learning simple ways to relax and prepare for sleep. The book introduces a range of techniques to help children unwind, including mindfulness activities such as Resting Pose and Floating on a Cloud. It also explores the benefits of a calming bedtime routine, limiting screen time and getting enough physical activity during the day. Whether children are bursting with energy, feeling worried or simply convinced they are not tired, Elmo Isn't Sleepy! aims to offer reassurance and practical strategies to make settling down a more positive experience. Through Elmo's familiar adventures, the book helps families start conversations about why sleep matters, how rest restores energy and how children can feel ready for the things they love doing when morning comes.